Early clinical trial experience with vaccine therapies in non-small-cell lung cancer

Ho, Cheryl; Ochsenbein, Adrian F; Gautschi, Oliver; Davies, Angela M (2008). Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clinical lung cancer, 9 Suppl 1, S20-S27. New York, N.Y.: Elsevier 10.3816/CLC.2008.s.004

Full text not available from this repository. (Request a copy)

Cancer immunotherapy has made great progress because of advances in immunology and molecular biology. Increased understanding of mechanisms by which lung cancer cells escape the immune system and recognition of key tumor antigens and immune system components involved in tumor ignorance have led to the development of a variety of lung cancer vaccines. Immunotherapy has advanced from using nonspecific immunomodulatory agents to lung cancer-specific tumor antigens and tumor cell-derived vaccines. While understanding of immune processes and malignancy has improved, there is great opportunity for further research of vaccine therapies in non-small-cell lung cancer. Herein, we review the development and evolution of early lung cancer vaccine trials.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Ochsenbein, Adrian and Gautschi, Oliver

ISSN:

1525-7304

ISBN:

18540531

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:02

Last Modified:

08 Jun 2016 10:45

Publisher DOI:

10.3816/CLC.2008.s.004

PubMed ID:

18540531

Web of Science ID:

000253386300004

URI:

https://boris.unibe.ch/id/eprint/27096 (FactScience: 102216)

Actions (login required)

Edit item Edit item
Provide Feedback